elotuzumab + thalidomide + dexamethasone

This is a combination therapy consisting of **elotuzumab** (a humanized IgG1 monoclonal antibody), **thalidomide** (an immunomodulatory agent), and **dexamethasone** (a synthetic glucocorticoid corticosteroid). This combination has been explored in clinical research for the treatment of relapsed or refractory multiple myeloma, but is not a standard or approved regimen—most approvals and established use involve elotuzumab with lenalidomide or pomalidomide plus dexamethasone, not thalidomide. Elotuzumab targets Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7, also known as CS1), which is highly expressed on myeloma cells and natural killer (NK) cells. It mediates its effect through NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC), direct NK cell activation, and macrophage-mediated antibody-dependent cellular phagocytosis (ADCP)[2][4][6]. Thalidomide, an immunomodulatory drug, has anti-angiogenic, anti-inflammatory, and direct anti-myeloma effects, acting through multiple mechanisms including modulation of the immune microenvironment and inhibition of tumor necrosis factor alpha. Dexamethasone is a potent corticosteroid that reduces inflammation and exerts anti-myeloma effects. This regimen is in clinical investigation for multiple myeloma and is not currently approved by regulatory agencies as a fixed combination.